Ksenia Matlawska-Wasowska, PhD

Ksenia Matlawska-Wasowska, PhD

Faculty Titles
Research Assistant Professor,
Office of Pediatric Research

Research Program
Cellular and Molecular Oncology

Graduate School
Doctoral Degree
University of Lodz, Poland (2007)
Biology (Genetics, Cell Biology)

Master of Science
University of Lodz, Poland (2002)
Cytogenetics, Cell Biology

Postdoctoral Associate
University of New Mexico (2009-2012)
Cell Biology, Hematology

Postdoctoral Fellow
National University of Ireland (2007-2009)
Cell Biology, Microbiology

Expertise, Certifications and Memberships
Full Member, Children's Oncology Group
Professional Member, American Society of Hematology
Professional Member, European Hematology Association

Personal Statement

I am a cell biologist with broad experience in cancer immunobiology, immunotherapy and research interests in pediatric acute lymphoblastic leukemia (ALL). My interests focus on biology of ALL, developing new biomarkers for leukemia treatment and risk-classification, and testing new leukemia drug candidates. My goal is to establish a successful research program, which will identify genes, signatures and epigenetic alterations associated with high-risk T-cell lineage ALL (T-ALL). For the past few years I have been working on ALL projects and investigated the efficacy of novel monoclonal antibodies, immunotoxins and small inhibitors in the treatment of this disease. My first author publications in Leukemia document my extensive experience in molecular and cell biology including assessment of cell-cell interactions, gene expression profiling, modification of cell signaling pathways and in vivo xenograft models. As a result of my interests with monoclonal antibodies, I developed a pyrosequencing-based diagnostic assay for FcγRIII allotype classification that could be used to stratify patients undergoing therapy with monoclonal antibodies (pending patent application). Currently my research focuses on the development of prognostic markers for T-ALL risk classification and identification of novel drug targets using genome-wide analyses. I am a Member of the Children’s Oncology Group (COG) where I have the opportunity to address important biological questions related to translational research in leukemia pathobiology and clinical trials. I am a PI of the COG AALL15B1-Q biology study on synthetic lethality in T-ALL and patient-derived xenograft models. Building on this foundation I am eager to study aberrant gene expression and genomic lesions found in T -ALL to improve patient risk-classification and identify new potential therapeutic targets. In our ongoing study we propose to investigate the roles of SOCS5 and other negative regulators of cytokine signaling in T -ALL migration and CNS infiltration. My extensive experience in cell and molecular biology, murine xenograft models, and recently in gene expression profiling puts me in a unique position to pursue the goals of our new research project and provide the opportunity for professional development.